RxDoctor Payments Data

Edward Dempsey, DO

Internal Medicine · Herndon, PANPI 1396785093

Payments from drug & device makers

$759in general payments, 2019–2025

Across 41 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$346
  • Harmony Biosciences LLC$63
  • GSK$54
  • AbbVie$54
  • Novo Nordisk$44
  • 3b Medical, Inc.$36
  • plus $163 from 7 others

What the payments were for

  • Food & beverage$72095%
  • Education$395%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$759 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$339,843
Medicare patients
884
Services billed
3,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban160$134,878
JardianceEmpagliflozin100$97,601
TrulicityDulaglutide55$62,377
XareltoRivaroxaban41$48,938
OzempicSemaglutide41$39,326
JanuviaSitagliptin Phosphate38$38,430
FarxigaDapagliflozin Propanediol25$25,766
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$21,840
TradjentaLinagliptin23$21,432
MyrbetriqMirabegron21$12,954
ShingrixVaricella-Zoster Ge/As01b/Pf40$8,317
LinzessLinaclotide14$8,021
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$7,228
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$6,794
SymbicortBudesonide/Formoterol Fumarate17$6,790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$30$62,37755 claims
Johnson & JohnsonXarelto, Invokana$33$55,39653 claims
Novo NordiskOzempic, Levemir$44$41,16659 claims
GSKTrelegy Ellipta, Shingrix, Anoro Ellipta$54$36,22775 claims
AstraZenecaFarxiga, Symbicort$12$32,55642 claims
AbbVieLinzess$54$8,02114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Herndon

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →